Focal Segmental Glomerulosclerosis Clinical Trials in New York, New York
7 recruitingNew York, New York
Showing 1–7 of 7 trials
Recruiting
Phase 2
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 4
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
Kidney TransplantFocal Segmental GlomerulosclerosisProteinuria+1 more
Travere Therapeutics, Inc.20 enrolled9 locationsNCT07219121
Recruiting
Not Applicable
NEPTUNE Match Study
Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting
Phase 1Phase 2
AMPK-activation by Metformin in FSGS: AMP-FSGS
Focal Segmental Glomerulosclerosis
Yale University30 enrolled2 locationsNCT06090227
Recruiting
Phase 2
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting
Not Applicable
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC35 enrolled12 locationsNCT02235857
Recruiting
Not Applicable
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC35 enrolled10 locationsNCT04065438